HCA Healthcare, Inc. (HCA)
NYSE · Price as of · Delayed Quote
- Analysts21
- Implied upside+5.2%
- Target range$380.00 to $579.00
- EPS expected$6.74 -3.2%
- A year ago$6.96
- Revenue expected$19.37B +1.1%
- Estimate range$5.83 to $7.35
Congress trades
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2026-06-30 | William R. Keating MA | Purchase | $15,001 - $50,000 | |
| 2026-06-17 | Jared Moskowitz FL | Purchase | $1,001 - $15,000 |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 8-K | July 29, 2026 | 8-K |
| 10-Q | July 28, 2026 | 10-Q |
| 8-K | July 24, 2026 | 8-K |
| 8-K | July 14, 2026 | 8-K |
| 8-K | June 18, 2026 | 8-K |
| 4 | May 11, 2026 | 4 |
| 4 | April 30, 2026 | FORM 4 |
| 4 | April 30, 2026 | FORM 4 |
Frequently asked questions
When does HCA report earnings?
HCA Healthcare, Inc. (HCA) is scheduled to report quarterly results on October 23, 2026 (estimated). The 19-analyst consensus is $6.74 per share on revenue of $19.37B for the quarter ending September 30, 2026, against $6.96 and $19.16B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for HCA?
21 analysts cover HCA Healthcare, Inc. (HCA). The consensus rating is Buy. The average price target is $451.48, in a range of $380.00 to $579.00.
Are insiders buying or selling HCA?
We have no qualifying Form 4 insider purchases or sales on record for HCA Healthcare, Inc. (HCA). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see HCA SEC filings?
Recent filings are listed on this page, newest first. The latest is an 8-K filed July 29, 2026.